BioSpace News Archive

Apellis Pharmaceuticals Inc. announced that on August 6, 2019, the Company approved the grant of an equity award to a new employee with a grant date of November 1, 2019 as an equity inducement award outside of the Company’s 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company.

CRH Medical Corporation, announced financial and operating results for the three months ended September 30, 2019..

Aeterna Zentaris Inc. reported its financial and operating results for the third quarter ended September 30, 2019..

AVITA Medical announced that the company will be added to the S&P/ASX 200 index, effective upon market open on 14 November 2019, two months after being added to the S&P/ASX 300 index.

TELA Bio, Inc. announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions, for gross proceeds of $52.0 million.

CNS Pharmaceuticals, Inc., a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, announced the pricing of its initial public offering of 2,125,000 shares of common stock at an offering price of $4.00 per share.

Partnership backed by robust clinical evidence, showing value of an integrated approach to infection prevention

Phase two of this grant proves CorTechs Labs’ PETQuant™ to be clinically and commercially viable

This collaboration will lay the groundwork for Optina’s future pivotal clinical trial.

Merz Pharma Canada Ltd., an affiliate of the global Merz Pharma Group, has announced that Health Canada has provided marketing authorization for additional indications for Xeomin Cosmetic® (botulinum toxin type A, free from complexing proteins), which include use in adults for the temporary improvement in the appearance of moderate to severe horizontal forehead lines and lateral canthal lines (crow’s feet)